secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2023-10-27T23:59:59+00:00
Accession:  0001104659-23-112166
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq Panel grants TransCode continued listing extension to Jan 22, 2024
-------------------------------------------------------------------------

- Company must provide update on meeting stockholders' equity requirement by Nov 14, 2023 after Q3 10-Q filing.
- By Jan 22, 2024, must demonstrate long-term compliance with Nasdaq's $2.5M stockholders' equity rule.
- Panel cannot extend listing beyond Jan 22 if compliance not achieved; conditions may be reconsidered.
- Company must promptly notify Nasdaq of any events that could affect compliance during exception period.
- Previously received delisting determination after Staff rejected compliance plan; hearing held Oct 5, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923112166/0001104659-23-112166-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923112166/tm2329299d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-112166

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer